AFFILIATIONS
1 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
2 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
3 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
4 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
5 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
6 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
7 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
8 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
9 Department of Hematology,Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
ABSTRACT
Objective To compare the efficacy and safety of iptacopan and eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) who were complement inhibitor (CI) naive.
Methods This retrospective study collected data from patients with PNH who received treatment with iptacopan or eculizumab at Peking Union Medical College Hospital between February 2023 and December 2025. Clinical data and changes in clinical manifestations and laboratory indicators were collected at 1, 3, and 6 months and during subsequent follow-up. Results A total of 120 patients were included (63 iptacopan, 57 eculizumab), with median follow-up durations of 15 (range, 6–24) and 24 (6–39) months, respectively. Hemoglobin normalization rates were significantly higher in the iptacopan group than in the eculizumab group (82.5% vs. 15.8% at 6 months, 87.2% vs. 25.5% at 12 months, and 84.6% vs. 34.5% at 24 months; all P < 0.01). Transfusion independence was achieved in 100% and 90% of patients, respectively. Lactate dehydrogenase normalization favored iptacopan (75.8% vs. 52.6%, P = 0.008) at 1 month, whereas converged or reversed at later time points (66.7% vs. 63.8% at 12 months; 53.8% vs. 62.1% at 24 months (P>0.05). Breakthrough hemolysis occurred less frequently with iptacopan (11.5 vs. 29.1 per 100 patient-years, P = 0.023). Adverse event rates were comparable (45.9 vs. 41.7 per 100 patient-years, P = 0.735) between the two groups. Clinically significant extravascular hemolysis was observed only in the eculizumab group (35.1%, 22.6%, and 13.6% at 6, 12, and 24 months). Infection-related serious adverse events were observed one in the iptacopan group and two in the eculizumab. No new thrombotic events or breakthrough meningococcal/pneumococcal infections occurred in either group.
Conclusions In this real-world cohort, iptacopan was associated with more favorable hemoglobin responses and comprehensive hemolysis control compared with eculizumab in CI naïve PNH patients.
DISCLOSURES
Leyu Wang: No relevant conflicts of interest to declare.